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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.022Preeclampsia is a major pregnancy complication with potential short- and long-term consequences for
both mother and fetus. Understanding its pathogenesis and causative biomarkers is likely to yield
insights for prediction and treatment. Herein, we provide evidence that transthyretin, a transporter of
thyroxine and retinol, is aggregated in preeclampsia and is present at reduced levels in sera of
preeclamptic women, as detected by proteomic screen. We demonstrate that transthyretin aggregates
form deposits in preeclampsia placental tissue and cause apoptosis. By using in vitro approaches and
a humanized mouse model, we provide evidence for a causal link between dysregulated transthyretin and
preeclampsia. Native transthyretin inhibits all preeclampsia-like features in the humanized mouse model,
including new-onset proteinuria, increased blood pressure, glomerular endotheliosis, and production of
anti-angiogenic factors. Our ﬁndings suggest that a focus on transthyretin structure and function is
a novel strategy to understand and combat preeclampsia. (Am J Pathol 2013, 183: 1425e1436; http://
dx.doi.org/10.1016/j.ajpath.2013.07.022)Supported by NIH grant P20RR018728 (J.P.), National Institute of
Environmental Health Sciences grant P42ES013660 (S.S.), and Rhode
Island Research Alliance Collaborative Research Award 2009-28 (S.S.).
Disclosures: A patent application (US patent 13/147,993) for composi-
tions, formulations, and methods for treating preeclampsia-type disorders of
pregnancy was ﬁled in 2010.Preeclampsia occurs in 5% to 8% of pregnancies worldwide
and is a major cause of fetal and maternal morbidity and
mortality.1e3 It is a heterogeneous disease with varied pre-
sentations frommild self-limited hypertension and proteinuria
to severe forms with signiﬁcant end-organ dysfunction and
HELLP syndrome (hemolysis, elevated liver enzymes, and
low platelets).3 Although the cause of preeclampsia and its
appropriate treatment remain elusive, this syndrome has been
proposed to reﬂect at least two stages of complications during
pregnancy. These begin with preclinical manifestations at the
maternal-fetal interface, followed by systemic clinical symp-
toms.1,2 Hypertension, proteinuria, and edema, with a variable
degree of fetal growth restriction, are the cardinal features of
preeclampsia.3 Because the placenta is the nutritional and
immunological gateway to normal fetal development and
pregnancy outcome, placenta-related events are believed to bestigative Pathology.
.central to the pathogenesis of this disease. Evidence exists for
the release of disease-initiating molecules into maternal
circulation that triggers the clinical symptoms.1,4 Placental and
systemic anomalies reﬂected by circulating placental debris,
inﬂammation, impaired remodeling of spiral arteries, placental
hypoxia/ischemia, excess production of anti-angiogenic
factors [soluble fms-like tyrosine kinase-1 (sFlt-1)], and
soluble endoglin (sEng), and angiotensin receptor autoanti-
bodies have all emerged as contributors to the pathophysio-
logical characteristics of preeclampsia.2,4e14
Kalkunte et alPreeclampsia has remained enigmatic because of lack of
well-deﬁned etiology and animal models. Although normal
mice do not develop preeclampsia spontaneously, mouse
models have been judged to be particularly useful to uterine
diseases and pregnancy complications because many simi-
larities in female reproduction and placentation have been
identiﬁed between the two species.15 Moreover, their trac-
table genetics provide an effective way to probe mechanisms
more deeply than many other species.15e17 We recently
showed that sera from preeclamptic women could function
as a source of novel causative factors that induced hyper-
tension, proteinuria, and kidney pathological characteristics,
as well as intrauterine growth restriction (IUGR), in IL-
10/ mice in a pregnancy-speciﬁc manner.18 IL-10 func-
tions as a potent vascular and anti-inﬂammatory cytokine
and has been shown to be present at signiﬁcantly reduced
levels in preeclampsia placental tissue.19,20 Preeclampsia
serum (PES) was found to disrupt endovascular cross talk
between trophoblasts and endothelial cells and to induce
placental hypoxia and excess production of sFlt-1 and
sEng,18 soluble factors known to precipitate maternal
symptoms.21,22 These results from our serum-based hu-
manized mouse model suggest that the pathophysiological
characteristics of preeclampsia are more complex than
previously thought and are likely to involve interactions and
dysregulation of multiple factors. By using serum proteomic
screening by surface-enhanced laser-desorption ionization-
time-of-ﬂight (SELDI-TOF), our results suggest that PES
contains a reduced abundance of transthyretin, a plasma
transport protein for the thyroid hormone, thyroxine, and
retinol-binding protein.23 More important, transthyretin has
been widely studied for its role in amyloid diseases associ-
ated with protein misfolding and aggregation, resulting in
deposits of toxic, ﬁbrillar aggregates in speciﬁc organs.24e26
Dysregulated or reduced transthyretin has also been impli-
cated in Alzheimer disease, and overexpression of a wild-
type human transthyretin transgene has been shown to
ameliorate the disease in the transgenic murine model of
human Alzheimer disease.27,28 Transthyretin in its native
form assumes a homotetrameric quaternary conﬁguration
(approximately 14 kDa per monomer). Post-translational
modiﬁcations of the monomer result in detection of several
isoforms.29 Circulating transthyretin is also a validated
marker of malnutrition and has a putative role in oocyte
maturation and inﬂammation.30e32 Although the presence of
transthyretin during implantation in mice and in the placenta
and trophoblasts in humans has been reported,33,34 its
functional role in normal pregnancy or adverse pregnancy
outcomes has not been recognized. We hypothesize that
transthyretin in preeclampsia is structurally and functionally
dysregulated and contributes to the onset of this serious
pregnancy complication. Herein, we present complementary
in vitro and in vivo approaches, which show that endoge-
nously altered transthyretin is a preeclampsia-causing agent
and that native transthyretin has the ability to block the onset
of preeclampsia-like features.1426Materials and Methods
Human Subjects
Preeclampsia was deﬁned by new-onset systolic and dia-
stolic blood pressures of >140 and 90 mm Hg, respectively,
and proteinuria (>300 mg of protein in a 24-hour urine
collection or a random urine protein/creatinine ratio of
>0.3) after 20 weeks’ gestation. Severe preeclampsia was
further deﬁned by systolic and diastolic blood pressures of
>160 and 110 mm Hg, respectively. For the purposes of this
study, we followed the exclusion and inclusion criteria as
described elsewhere.18 Gestational age-matched healthy,
normotensive, pregnant women (the normal group) were
included as controls. Blood was obtained from pregnant
women during 32 to 36 weeks of pregnancy with informed
consent, under the approved protocols by the Institutional
Review Boards of Women and Infants Hospital of Rhode
Island (Providence), Linkoping University Hospital (Link-
oping, Sweden), and University of Jena (Jena, Germany).
Serum was separated and frozen as aliquots at 80C until
further use. Patient characteristics included for the study are
provided in Supplemental Table S1.Proteomics and Two-Dimensional Gel Electrophoresis
Two different groups of gestational age-matched serum
samples were analyzed by SELDI-TOF. In the ﬁrst group,
normal pregnancy serum (NPS) (n Z 16) or PES (n Z 53)
samples were analyzed by SELDI-TOF using the anionic
exchange Q10 chip and analyzed with a ProteinChip Reader
(series 4000; Bio-Rad, Munich, Germany). The bioin-
formatical analysis was performed using Ciphergen Express
Client version 3.0 software. Arrays were exposed to 2200 nJ
laser energy to detect proteins in the range of 2 to 20 kDa
and to 3500 nJ for proteins in the range of 20 to 200 kDa at
a pressure of <150 mPa. Calibration was performed exter-
nally through the use of a protein molecular weight standard
kit (Bio-Rad, Waltham, MA). A similar SELDI-TOF anal-
ysis was performed using an additional second group of
serum samples from normal pregnancy (n Z 7) and pre-
eclampsia (nZ 8) from an independent cohort of subjects to
validate the proteomics ﬁndings from the ﬁrst group.
To identify the protein(s) that is altered in PES, we per-
formed two-dimensional gel electrophoresis using both NPS
and PES samples. Brieﬂy, 50 mL of serum was precipitated
in 50 mL of 20% triﬂuoroacetic acid and 50% acetonitrile for
30 minutes at 20C. Protein pellets were washed twice in
ice-cold 80% acetone and rehydrated for 48 hours in 125 mL
of 2% immobilized pH gradient buffer (0.5% 3-[(3-
cholamidopropyl)-dimethylammonio]-1-propane-sulfonate,
8 urea, and 0.002% bromophenol blue). Concentrated
protein solution was applied on a 7-cm nonlinear Im-
mobiline DryStrip pH 3-11 (GE Healthcare, Boston, MA)
through incubation for 14 hours under mineral oil using
a Dry Strip reswelling tray. Isoelectric focusing wasajp.amjpathol.org - The American Journal of Pathology
TTR and Pathogenesis of Preeclampsiaperformed using a Multiphor II Flatbed Electrophoresis
System (Amersham, Piscataway, NJ). Subsequently, the 2%
immobilized pH gradient strips were transferred into 10 mL
of an equilibration solution consisting of 23% glycerol, 4.6
mol/L urea, 30 mmol/L Tris(hydroxymethyl)aminomethane
(Tris), 0.03 mmol/L SDS with 65 mmol/L dithiothreitol
(DTT) for 15 minutes, followed by incubation in a 10-mL
equilibration solution (135 mmol/L iodoacetamide and Serva
Blue G-250). The second dimension was performed using
a NuPAGE 4% to 12% Bis-Tris Zomm Gel (Invitrogen,
Carlsbad, CA) in a Novex Mini- Cell (Invitrogen). Spots in
the appropriate molecular mass range were cut out from the
gel, destained, dried, and trypsin digested. The peptide
ﬁngerprints obtained from trypsin-digested spots were
analyzed using the ProFound database (The Rockefeller
University, http://prowl.rockefeller.edu/prowl-cgi/profound.
exe, last accessed August 20, 2011).
ELISA Data
Serum levels of human transthyretin were measured by
using a transthyretin-speciﬁc enzyme-linked immunosor-
bent assay (ELISA) kit (ALPCO kit, Salem, NH), according
to the manufacturer’s protocol. Brieﬂy, the serum samples
were diluted 1:10,000 or 1:20,000 in wash buffer and
incubated on a precoated plate for 1 hour at room temper-
ature, washed, and incubated with peroxidase-labeled anti-
body for 1 hour. Color was developed using TMB substrate
for 10 minutes, stop solution was added, and the plate was
read at 450 nm. The serum levels of mouse sFlt-1 and sEng
were measured by ELISA (R&D Systems, Minneapolis,
MN), as per the manufacturer’s protocol.
Immunodepletion of Transthyretin
Approximately 10 mL of protein A agarose beads was
washed in coimmunoprecipitation buffer and incubated with
either 5 mL anti-human transthyretin antibody (whole anti-
serum; Sigma-Aldrich, St. Louis, MO) or isotype IgG
(Dako, Carpentaria, CA). After blocking with 3% milk and
being washed, the beads were incubated with serum (1:50
dilution). The supernatants after centrifugations were used
for SELDI-TOF analysis or for in vivo experiments.
Immunodepletion of transthyretin was conﬁrmed by using
Western blot analysis.
Immunoprecipitation of Transthyretin
Transthyretin antibody-bound g bind Plus Sepharose beads
were incubated with 100 mL serum overnight and centri-
fuged, and the immunoprecipitates and supernatant were
used for experiments. Western blot analysis using a
reducing gel conﬁrmed the depletion of transthyretin (TTR).
For protein-protein interaction studies, individual serum
samples were spiked with equal amounts of puriﬁed sEng
protein before immunoprecipitation.The American Journal of Pathology - ajp.amjpathol.orgIn Vivo Studies
All animal protocols were approved by the Lifespan Insti-
tutional Animal Care and Use Committee. IL-10/ mice
with a C57BL/6 background were housed and mated in
a speciﬁc pathogen-free facility under the care of the Central
Research Department of Rhode Island Hospital. All mating
experiments were repeated at least three times, with at least
four to seven mice per treatment. The day of vaginal plug
appearance was designated gestational day (gd) 0. Animals
received i.p. injections of severe preeclampsia serum (100
mL) per mouse or an equivalent volume of normal preg-
nancy serum as control on gd 10, as described.18 For gain-
of-function studies, PES was incubated with 20 or 100 mg
transthyretin protein puriﬁed from human serum (AbD
Serotec, Oxford, UK) at 37C for 15 minutes before injec-
tion on gd 10. Similarly, immunoprecipitate or supernatant
obtained from serum immunodepleted using transthyretin or
isotype antibody (Dako, Glostrup, Denmark), as described
later, was injected on gd 10.Assessment of Proteinuria, Blood Pressure, Fetal
Weight, Renal Pathological Characteristics, and ELISA
On gd 16, the animals were transferred to metabolic cages for
24-hour urine collection for assessing proteinuria. Total
urinary albumin was measured using Albumin (mouse)
ELISA kit (ALPCO Diagnostics, Germany). To normalize
the albumin, urinary creatinine was measured using Metra
Creatinine Kit (Quidel Corporation, San Diego, CA),
according to the manufacturer’s protocol. Proteinuria was
represented as the ratio of urinary albumin/creatinine and was
expressed as mg/mg. On gd17, blood pressure was recoding
by the tail-cuff method, as described earlier.14,18 The animals
were then euthanized, and the uteroplacental units were
surgically removed, the placenta was separated from the fetus
and imaged, and fetal weights were recoded. Kidney tissue
was harvested from gd17 mice, ﬁxed in 10% buffered
formalin, and stained with H&E and PAS for histopatholog-
ical examination, as previously described.14,18 Morpholog-
ical changes were recorded using SPOT Advanced software
(Diagnostic Instruments Inc., Sterling Heights, MI) at 100
magniﬁcation (Nikon Eclipse 80imicroscope, Tokyo, Japan).In Vitro Three-Dimensional Tube Formation Assay
A three-dimensional tube formation assay has been used to
mimic in vitro the endovascular interaction between
trophoblasts and endothelial cells. Brieﬂy, the ﬁrst-trimester
extravillous trophoblast cell line, HTR8,35 and 2.5  104
human umbilical cord endothelial cells were co-cultured on
Matrigel in the presence of NPS or PES, as described.18,36
For gain- or loss-of-function studies, PES used in these
experiments was either incubated with a different concen-
tration of transthyretin (AbD Serotec) or immunodepleted1427
Kalkunte et alusing transthyretin (Dako), or isotype antibody was used for
endovascular activity.
Transthyretin Aggregation Studies
Phosphate-buffered serum from normal pregnancy or
preeclampsia, 0.4 mg/mL human transthyretin, or 0.4 mg/
mL bovine serum albumin (BSA) were diluted 1:1 with
a buffer (100 mmol/L KCl and 1 mmol/L EDTA) to achieve
the desired pH (sodium citrate for pH <3.2, sodium acetate
for pH 3.5 to 5.3, and sodium phosphate buffer for pH
>5.3).37 The solutions were incubated at 37C in Eppendorf
tubes. At measurement, the tubes were vortex mixed for 5
seconds, and turbidity was measured at 330 nm in triplicate
using a nanodrop. The percentage of aggregation was
calculated, with the 100% value corresponding to the
maximum signal of native TTR protein or PES. All
measurements were made in triplicate in at least two inde-
pendent experiments.
Western Blot Analysis
Serum samples or immunoprecipitates were separated on
12% native PAGE (aggregated TTR) or precast 4% to 15%
SDS-PAGE gel (TTR monomers) under reducing conditions
and electroblotted on a polyvinylidene diﬂuoride membrane.
The membranes were subsequently blocked with 5% milk in
PBS with Tween 20 for 1 hour at room temperature. Blots
were then probed with rabbit anti-human TTR antibody
(1:500; Dako, Glostrup, Denmark) in 1% PBS with Tween
20 for 1 hour at room temperature. The bands were visu-
alized using horseradish peroxidaseeconjugated secondary
antibodies (a Diagnostics, San Antonio, TX), followed by
enhanced chemiluminescence (Pierce, Rockford, IL). The
protein bands were recorded using a Konica SRX 101A
developer (Tokyo, Japan). For protein-protein interaction
studies, transthyretin immunoprecipitates from NPS or PES
were probed under reducing conditions with biotinylated
goat anti-human sEng or biotinylated mouse anti-human
retinol binding protein (RBP)-4 (1:2000).
Far Western Analysis
Recombinant retinol binding protein-4, 3.75 mg (Fitzgerald
Industries, Acton, MA), 0.75 mg endoglin (R&D Systems),
1.5 mg sFlt-1 (Fitzgerald Industries), and 6 mg vitronectin
(Promega, Madison, WI) were separated on a 4% to 15%
precast SDS gel (Bio-Rad) and electroblotted on a poly-
vinylidene diﬂuoride membrane. The proteins were dena-
tured and renatured on the membrane using a modiﬁed AC
buffer [100 mmol/L NaCl, 20 mmol/L Tris (pH 7.6), 0.5
mmol/L EDTA, 10% glycerol, 0.1% Tween-20, 2% BSA,
and 1 mmol/L DTT] by gradually reducing the guanidine-
HCl concentration, as per the protocol described.38 The
membranes were subsequently blocked with 5% BSA in
PBS with Tween 20 for 1 hour at room temperature and1428incubated with 10 mg TTR protein (AbD Serotec) in
a modiﬁed protein binding buffer [100 mmol/L NaCl, 20
mmol/L Tris (pH 7.6), 0.5 mmol/L EDTA, 10% glycerol,
0.1% Tween-20, 2% BSA, and 1 mmol/L DTT] overnight at
4C. Blots were then probed with 1:500 TTR antibody
(Dako) in 1% PBS with Tween 20 containing BSA for 1
hour at room temperature. The bands were visualized using
horseradish peroxidaseeconjugated secondary antibodies
(a Diagnostics), followed by enhanced chemiluminescence
(Pierce). The protein bands were imaged (Gel Document
System, GDS 8000; Bio-Rad Laboratories, Hercules, CA).
IHC and Thioﬂavin S Staining
Antigen retrieval of deparafﬁnized term human placental
sections was performed using a citric acidebased unmask-
ing solution (Vector, Burlingame, CA) and microwave oven
technique. Sections from normal and preeclampsia speci-
mens were blocked for 1 hour with 20% goat serum and
incubated with primary transthyretin polyclonal rabbit
antibody (1:400; Dako) in a humidiﬁed chamber for 1 hour
in room air, followed by biotinylated secondary anti-rabbit
antibody (VectaStain Elite Kit, Burlingame, CA) for 45
minutes. Immunolabeling was performed by a standard
avidin-biotin technique, as per the manufacturer’s protocol.
Labeling was developed with 0.05% 3,30-diaminobenzidine
(Sigma), and slides were counterstained with hematoxylin
(Fisher Scientiﬁc, Kalamazoo, MI). Human transthyretin in
the mouse placenta was probed using transthyretin poly-
clonal rabbit antibody (1:200, overnight at 4C; Dako) and
detected using Cy-3econjugated anti-rabbit IgG (1:100;
Invitrogen). Sections were counterstained with DAPI. Thi-
oﬂavin S staining was performed as described.39 Brieﬂy,
deparafﬁnized sections were sequentially treated with 0.25%
potassium permanganate solution for 5 minutes, bleaching
solution (1% potassium metabisulﬁte and 1% oxalic acid)
for 5 minutes, rinsed with water, and stained with 0.02%
thioﬂavin S (Sigma) for 3 to 5 minutes. Finally, the sections
were rinsed twice with 80% alcohol and water, dehydrated,
and mounted with coverslips.
TUNEL Staining
TUNEL staining for apoptotic nuclei was performed using
the ApopTag Peroxidase in Situ Apoptosis Detection Kit
(Millipore, Billerica, MA), according to the manufacturer’s
instructions. Labeling reactions were performed for 60
minutes at 37C in a humidiﬁed chamber. Color develop-
ment was accomplished using 3,30-diaminobenzidine for 5
minutes. Sections were counterstained with methyl green.
Statistical Analysis
SELDI-TOF raw data were analyzed using the software
Ciphergen express client version 3.0 in two separate parts, in
accordance with laser energy. First, peaks were automaticallyajp.amjpathol.org - The American Journal of Pathology
Figure 1 Surface enhanced laser desorption ionization-time-of-ﬂight (SELDI-TOF) andbiochemical analyses of transthyretin in preeclampsia serum.A: Preeclampsia
serum(PES) (nZ53) andnormal pregnancy serum(NPS) (nZ16)were analyzedby SELDI-TOF in themolecularmass rangeof 2 to200kDa. In theentiremolecularweight
(MW) range, the time ofﬂight scatterplot showsmost signiﬁcant changes (reduction) in themedian intensities of a 14-kDa protein group in PESwhen comparedwithNPS
samples.B: Isoelectric point (pI) andmolecular weight of a protein spot (approximately 14 kDa) separated by two-dimensional gel electrophoresis from a representative
NPS sampleareshown. Themass fragmentationpatternof the corresponding trypsin-digested spot andmolecularmass (m/z)of thepeptide fragments are also shown. The
sequence coverage obtained by comparisonwith the ExPASy database (P02766; Swiss Institute of Bioinformatics, http://www.expasy.org, last accessed August 20, 2011)
identiﬁed theprotein spot (approximately14kDa) tobe transthyretin.C: NormalizedProteinChiparrayproﬁles are shownofa representativeNPS sample immunodepleted
with a transthyretin-neutralizing antibody or an isotype-matched antibody. Successful immunodepletion of transthyretin (pink highlighted area) conﬁrmed that the
protein with a molecular mass of approximately 14 kDa was transthyretin. D: Comparison of transthyretin protein peaks (molecular mass of approximately 14,000 Da) in
NPS, PES, and commercial human transthyretin (cTTR) is shown.
TTR and Pathogenesis of Preeclampsiadetected and manually adjusted, followed by linear normali-
zation to compensate for differences in total protein concen-
tration. Spectra showing normalization factors <0.5 or >3,
which shows low quality of the spectra, were excluded from
analysis. Subsequently, P values were calculated by using
a two-sided t-test (nZ 2 groups), a paired t-test (nZ 2 paired
groups), or single-factor/one-way analysis of variance (nZ
3 groups) for normally distributed data, and aU-test (nZ 2
groups), a Wilcoxon t-test (nZ 2 paired groups), or a Krus-
kal-Wallis H test (nZ 3 groups) for not normally distrib-
uted data. For normally distributed animal and ELISA data,
two-tailed Student’s t-tests were used in our analysis. P <
0.05 was considered signiﬁcant.
Results
Proteomic Analysis Reveals Reduced Levels of
Transthyretin in Preeclampsia Serum
We recently showed that PES, but not NPS, induces a full
spectrum of preeclampsia-like features in pregnant IL-10/
mice.18 To identify the potential causative factor(s) in PES,
we undertook a comparative proteomic analysis of PES andThe American Journal of Pathology - ajp.amjpathol.orgNPS. PES and control gestational age-matched NPS were
analyzed by SELDI-TOF (2 to 200 kDa). A protein of
approximately 14 kDa molecular mass was found to be
consistently present at reduced levels in PES (Figure 1A).
Because the number of NPS samples in initial analysis
was comparatively fewer than PES, this observation was
conﬁrmed using an independent cohort of 15 serum sam-
ples (Supplemental Table S2), where all four isoforms of
transthyretin were recorded at reduced intensities in PES.
Two-dimensional gel electrophoresis and peptide mass
fragmentation of the trypsin-digested spots identiﬁed an
approximately 14 kDa protein cluster that was determined to
be transthyretin by comparison with the ExPASy database
(Figure 1B) (P02766; Swiss Institute of Bioinformatics,
http://www.expasy.org, last accessed August 20, 2011). The
identity of the protein was further conﬁrmed by the loss of
transthyretin signal after its immunodepletion from NPS
(Figure 1C) and by direct comparison of the molecular mass
with commercial human transthyretin (Figure 1D). Each peak
in the group was assigned to be either native protein or
cysteinylated, cysteinglycinylated, and glutathionylated iso-
forms (Supplemental Figure S1). The identities of these
isoforms were based on their molecular mass, as described in1429
Figure 2 Transthyretin in preeclampsia is dysregulated and forms aggregates. A: Analysis of serum transthyretin in normal pregnancy serum (NPS) and
preeclampsia serum (PES) by ELISA. Transthyretin is present at signiﬁcantly reduced levels in PES (P < 0.001). B: Immunohistochemical (IHC) analysis using
transthyretin-speciﬁc antibody (Ab) shows strong transthyretin staining in the extravillous domain of human placental section from preeclampsia, not normal
pregnancy, in addition to staining in the trophoblast layer (arrows) lining the placental villi. Adjacent section of the same preeclampsia placenta shows intense
ﬂuorescence for amyloid-speciﬁc thioﬂavin S staining that overlaps with extracellular transthyretin-positive deposits. Additional placental tissue sections are
shown in Supplemental Figure S2. C: Comparative analysis of aggregation of puriﬁed transthyretin, NPS, PES, and albumin indicated by turbidity measurements
(330 nm) is shown as average values ofmultiple serum samples analyzed. All of the serum samples usedwere normalized to 0.4mg/mL transthyretin, as determined
by ELISA. PES showed a higher propensity to aggregate, as reﬂected by higher turbidity. On an average, eight different samples of NPS and PES were analyzed. D:
Experimentalﬂow chart for transthyretin IP and depletion is presented. SDS-PAGE immunoblotting shows the presence or absence of transthyretinmonomer in the
immunoprecipitate or supernatant of PES or NPS, respectively. E: Turbidity (330 nm) of supernatants obtained from transthyretin-depleted NPS or PES samples was
measured and expressed as percentage aggregation. Antibody-mediated transthyretin depletion abolished aggregation associated with PES. **P < 0.01.
Kalkunte et althe literature.40 As evident from the data, the relative abun-
dance of native transthyretin and all of its isoforms
was reduced in PES compared with NPS (Supplemental
Figure S1). In contrast, the level of albumin was un-
changed between PES and NPS samples.
Evidence for the Presence of Transthyretin Protein
Aggregates in Preeclampsia
We next examined whether the SELDI-TOF data could be
conﬁrmed by ELISA that recognizes all forms of trans-
thyretin. As shown in Figure 2A, the SELDI-TOF data were
conﬁrmed by ELISA and a signiﬁcant reduction (P < 0.001)
was observed in transthyretin levels between NPS (nZ 35)
and PES (n Z 35). However, our initial Western blot
analysis under reducing conditions provided contrasting
data in that when an equal amount of total serum protein
was probed for transthyretin between NPS and PES, it
resulted in a similar band intensity proﬁle. Because the protein
chips used in SELDI-TOF are derivatized to interact and1430sequester proteins according to their surface interaction
potential,41 it is possible that structurally altered transthyretin
in PES showed reduced binding efﬁciency. Similarly, anti-
bodies used in the ELISA kit may show poor afﬁnity for
altered transthyretin. In amyloid diseases, aggregation of
transthyretin leads to toxic tissue deposits.42e45This prompted
us to probe possible aggregation properties of transthyretin
in preeclampsia. We ﬁrst examined human placental tissue
from normal pregnancy and preeclampsia deliveries for
transthyretin immunostaining and deposits. When probed
with a transthyretin-speciﬁc antibody, preeclampsia placental
tissue, in general, showed intense transthyretin staining that
was particularly apparent in the extravillous trophoblast
domain regions, as assessed by perinatal pathologists
(Figure 2B and Supplemental Figure S2A). Furthermore,
staining with thioﬂavin S, a speciﬁc ﬂuorescent dye that
detects extracellular deposits,39 displayed an intense signal that
colocalizes with transthyretin-immunoreactive regions from an
adjacent placental section from preeclampsia, suggestive of the
amyloidal nature of transthyretin deposits (Figure 2B).ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Exogenous transthyretin inhibits preeclampsia-associated features in vitro and in vivo. A: Serum-induced and transthyretin-modiﬁed endovascular
interaction between endothelial cells (human umbilical cord endothelial cells, cell tracker red) and ﬁrst-trimester trophoblasts (HTR8, cell tracker green) was
analyzed by three-dimensional tube formation on Matrigel.18 Native transthyretin rescued tube formation disrupted by preeclampsia serum (PES). B: Reversal of
PES-induced intrauterine growth restriction (IUGR) by exogenous transthyretin in IL-10/ mice. A representative image of gd 17 fetus is shown. A total of ﬁve
animals were used in each condition. C: The average fetal weight from IL-10/ mice receiving different treatments was evaluated. D: Systolic blood pressure in
pregnant mice on gd 17 was evaluated in response to different treatments. E: Proteinuria in pregnant mice was assessed on gd 17 in response to various
treatments. The results are expressed as a ratio of albumin/creatinine excretion (mg/mg). All values represent means SD of at least 5 to 30 animals per group,
depending on the experiment. *P < 0.01, **P < 0.05 between PES and transthyretin treatment groups; yP < 0.05 between NPS and PES groups.
TTR and Pathogenesis of PreeclampsiaThioﬂavin S staining from additional placental tissue sections is
shown in Supplemental Figure S2B. These ﬁndings support our
contention that aggregated transthyretin forms extracellular
amyloid deposits in the placenta, which may cause toxic effects
and disrupt placental function.
Sera from Preeclampsia Patients Exhibit Increased
Propensity for Transthyretin-Speciﬁc Protein Aggregation
In solution, transthyretin and its mutant variants are known
to undergo pH-dependent monomerization and aggrega-
tion.37,42,43 Transthyretin aggregation in NPS and PES was
monitored by measuring solution turbidity at 330 nm,
a measurement previously considered valid for quantiﬁ-
cation of transthyretin misfolding and aggregation.37,42
Consistent with previous reports,42 puriﬁed (native) trans-
thyretin exhibited weak aggregated characteristics (tur-
bidity) between pH 3.5 and 4.5, with peak aggregation at
4.35, whereas albumin exhibited no turbidity over this pH
range (Supplemental Figure S2C). Under identical condi-
tions, we then assessed NPS and PES for intrinsic and
transthyretin-mediated aggregation.Asobserved inFigure 2C,
PES exhibited higher aggregation propensity than NPS.The American Journal of Pathology - ajp.amjpathol.orgTo assess transthyretin-mediated aggregation propensity
of PES, we performed experiments by immunodepleting
transthyretin, as shown in the scheme (Figure 2D). The
depletion of transthyretin in serum sampleswas conﬁrmed by
immunoblotting for the protein. Transthyretin antibody, not
isotype control IgG, depleted the protein (Figure 2D). In
protein aggregation studies at pH 4.35 (Figure 2E), depletion
of transthyretin in PES signiﬁcantly abolished aggregation,
conﬁrming its speciﬁc contribution in this process. Isotype
control antibody had a minimal effect on the aggregation
proﬁle of NPS or PES.
Exogenous Transthyretin Rescues PES-Induced
Disruption of in Vitro Three-Dimensional Tube
Formation and in Vivo Disease Features
We have previously shown that PES disrupts endovascular
cross talk between endothelial cells and trophoblasts,18,36
a process required for spiral artery remodeling. We next
evaluated the effect of native transthyretin on PES-mediated
disruption of three-dimensional tube formation between
endothelial cells and trophoblasts. Replenishment of PES with
exogenous transthyretin restored capillary tube formation in1431
Figure 4 Exogenous transthyretin rescues glomerular integrity and
inhibits production of sFlt-1 and sEng in preeclamptic IL-10/ mice. A:
Histopathological analysis of H&E- or periodic acid schiff (PAS)-stained
renal tissues from NPS, PES, or PESþ transthyretin-treated (5 mg/kg)
pregnant IL-10/ mice are shown. Original magniﬁcation, 100. The H&E
stain shows the normalization of PES-induced capillary occlusion, enlarged
glomeruli, and swollen endothelial cells by transthyretin treatment that is
comparable to NPS-treated control mice. PAS-based staining indicates that
transthyretin treatment reverses PES-induced inﬂammation of capillary
endothelial cells (endotheliosis). These pathological changes are absent in
the NPS-treated mice. A representative image from staining of at least
three animals per group is shown. B: Serum levels of mouse sFlt-1 from
pregnant IL-10/ mice obtained on gd 17 from different treatment groups
are shown. Treatment with 5 mg/kg transthyretin reverses the PES-induced
excess production of sFlt-1 in IL-10/ mice. C: Serum levels of mouse sEng
from pregnant IL-10/ mice obtained on gd 17 from different treatment
groups are shown. Treatment with transthyretin reverses the preeclampsia
serum (PES)-induced excess production of sEng to levels comparable to
normal pregnancy serum (NPS) treatment control group. All values are
expressed as means  SD obtained from at least ﬁve animals per treatment
group. *P < 0.05 represents the signiﬁcance between different treatment
groups.
Kalkunte et ala dose-dependent manner, whereas PES disrupted this inter-
action (Figure 3A). We next examined whether exogenous
human transthyretin could inhibit the PES-induced onset of
preeclampsia pathological characteristics in IL-10/ mice.
Co-administration of a single dose of 5 mg/kg transthyretin
and PES on gd10 prevented the PES-induced IUGR (Figure 3,
B and C), reversed PES-induced hypertension (Figure 3D),
and restored proteinuria (Figure 3E) to normal values. These
observations clearly suggest that exogenous (normal) trans-
thyretin has the potential to counter the effects of altered
transthyretin present in PES.
We have demonstrated that PES causes renal pathological
characteristics and induces production of anti-angiogenic
factors, sFlt-1 and sEng.18 Next, we evaluated whether
exogenous transthyretin inhibited production of sFlt-1 and
sEng and protected against glomerular endotheliosis in
response to PES. As shown in Figure 4A, human1432transthyretin prevented the PES-induced glomerular endo-
theliosis in pregnant IL-10/ mice, as suggested by H&E
and PAS staining. We assessed mouse serum levels of sFlt-1
and sEng in response to treatment with NPS, PES, or PES
spiked with transthyretin. As shown in Figure 4, B and C,
exogenous human transthyretin signiﬁcantly inhibited the
PES-induced increase of circulating sFlt-1 and sEng to
levels comparable to the NPS-treated group, suggesting that
dysregulated transthyretin affects overall preeclampsia
pathological characteristics and that native protein can blunt
all these contributing factors.
Evidence that Transthyretin Immunoprecipitated from
PES Induces Disease Features in Pregnant IL-10/
Mice
To obtain direct evidence that dysregulated transthyretin from
PES contributes to preeclampsia-like features in IL-10/
mice, we evaluated the effect of transthyretin immuno-
precipitated from NPS (NPS-transthyretin) or PES (PES-
transthyretin), as shown in the ﬂow chart (Figure 2D). The
presence of approximately equal amounts of transthyretin in
immunoprecipitates was conﬁrmed by using Western blot
analysis (Figure 2D). The administration of PES-transthyretin
on gd 10 resulted in IUGR, as indicated by reduced fetal
weight (Figure 5A), elevated hypertension (Figure 5B) and
proteinuria (Figure 5C), and induced production of sFlt-1
(Figure 5D). Furthermore, as shown in Figure 5E, adminis-
tration of PES-transthyretin resulted in signature features of
glomerular endotheliosis, including inﬂammation of endothe-
lium and swelling, as indicated by H&E and PAS staining. In
contrast, NPS-transthyretin did not cause signiﬁcant changes
in all of the parameters monitored. These ﬁndings provide
direct evidence that dysregulated transthyretin contributes to
preeclampsia-like features in pregnant IL-10/ mice.
Does PES transthyretin form toxic deposits in the mouse
placenta? We evaluated the placenta from NPS and PES-
transthyretinetreated IL-10/mice for human transthyretin.
As shown in Supplemental Figure S3, immunoprecipitated
transthyretin from both NPS and PES reached the placenta
(Supplemental Figure S3, C and D), whereas saline control
(Supplemental Figure S3A) or isotype-matched IgG-medi-
ated immunoprecipitates from PES showed no evidence of
human transthyretin (Supplemental Figure S3B). More
important, transthyretin antibody-mediated immunoprecipi-
tates from PES formed heavy deposits (Supplemental
Figure S3D) and caused apoptosis (Supplemental
Figure S3F) in the placental region, as assessed by TUNEL
staining. In contrast, although NPS-transthyretin reached the
placenta (Supplemental Figure S3C), it did not cause cell
death (Supplemental Figure S3E). These results suggest that
PES-transthyretin elicits toxic effects in the mouse placenta.
We also screened ﬂow through from transthyretin-
immunodepleted serum samples for their ability to cause
preeclampsia-like features in IL-10/mice. The basic premise
was that depletion of dysregulated transthyretin from PESajp.amjpathol.org - The American Journal of Pathology
Figure 5 Immunoprecipitated (IP) transthyretin from preeclampsia serum (PES) induces disease features in IL-10/ mice. Pregnant mice were injected
(i.p.) on gd 10 with transthyretin immunoprecipitate obtained from 100 mL normal pregnancy serum (NPS) or PES each, as described in Materials and Methods.
A: The average weight of fetal units derived from pregnant mice on gd 17 receiving different treatments is shown. B: The systolic blood pressure of pregnant
mice on gd 17 was evaluated in response to different treatments. C: Proteinuria (albumin/creatinine ratio, in mg/mg) is shown in response to various
treatments. PES-transthyretin caused signiﬁcant proteinuria compared with NPS-transthyretin. Isotype-matched IgG-mediated immunoprecipitation from PES
resulted in values similar to NPS, conﬁrming the validity of transthyretin-speciﬁc antibody. D: Transthyretin immunoprecipitate from PES induced excess
production of mouse sFlt-1 in pregnant IL-10/ mice. E: Histological analysis using H&E or periodic acid schiff (PAS) staining of renal tissue from pregnant
IL-10/ mice in response to transthyretin immunoprecipitates from NPS and PES is shown. A representative image from staining of at least three animals per
group is presented. All values represent means  SD of at least 3 to 18 animals per group. *P < 0.05 between treatment groups indicated.
TTR and Pathogenesis of Preeclampsiashould result in normal pregnancy, with no increased blood
pressure, new-onset proteinuria, and production of factors, such
as sEng. As shown in Figure 6, transthyretin-depleted PES
failed to induce blood pressure increase, proteinuria, and
production of sEng. PES treated with isotype-matched IgG still
maintained pathological characteristics compared with NPS.
Transthyretin Functions as a Binding Partner for
Anti-Angiogenic Protein sEng
Because transthyretin functions as a binding partner for th-
yroxine, RBP-4, and b-amyloid protein,23,28 we hypothesized
that native transthyretin could function as a scavenger proteinFigure 6 Transthyretin-immunodepleted preeclampsia serum (PES) fails to in
injected on gd10 in IL-10/ mice, and its effects on fetal size, blood pressure, pro
volume of normal pregnancy serum (NPS) or isotype-matched IgG-depleted PES. Im
blood pressure, proteinuria, or sEng levels, suggesting that dysregulated transthy
acteristics in IL-10/ mice. All values represent means  SD of at least three to
The American Journal of Pathology - ajp.amjpathol.orgfor preeclampsia-associated factors. Initially, we searched the
SELDI-TOFmass spectrometry proﬁle for additional proteins
that disappeared with transthyretin depletion in NPS. Along
with several proteins, the analysis suggested that a protein of
approximately 66.5 kDa could be a part of the complex
(Supplemental Figure S4 and Supplemental Table S3).
Because sEng is 67 kDa molecular weight and its levels in
preeclampsia are altered,7 we pursued the hypothesis that
transthyretin interacts with this protein. We conﬁrmed this
interaction using the Far Western technique, which depends
on binding of a prey protein to bait proteins.38 Native trans-
thyretin was used as the bait protein and puriﬁed sFlt-1, sEng,
and RBP-4 as prey proteins. RBP-4 was included as a positiveduce preeclampsia-like features. Transthyretin-depleted PES (100 mL) was
teinuria, and serum levels of sEng were compared with injection of an equal
munodepletion of transthyretin in PES fails to cause signiﬁcant changes in
retin in PES is responsible for induction of preeclampsia pathological char-
four animals per group. *P < 0.05 between treatment groups tested.
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Figure 7 Transthyretin binds to soluble endoglin and its possible mode
of action. A: Far Western blot showing the binding of transthyretin with
sEng and RBP-4 (red circle) and lack of binding to sFlt-1. Puriﬁed sFlt-1,
sEng, and RBP-4 were used as prey proteins, and puriﬁed human trans-
thyretin was used as probing bait protein. A representative immunoblot
from multiple independent experiments is shown. B: Proposed model
showing the role of upstream factors, such as hypoxia, acidosis, and stress,
in triggering aggregation of transthyretin that induces production of
anti-angiogenic factors and impairs the binding and scavenging of
preeclampsia-causing soluble factors.
Kalkunte et alcontrol. As shown in Figure 7A, transthyretin binds to sEng
and RBP4. We did not observe signiﬁcant binding of trans-
thyretin to sFlt-1 under these experimental conditions.
Discussion
In this study, we report novel ﬁndings associated with
dysregulated transthyretin in preeclampsia. By using PES
or transthyretin immunoprecipitated from PES, we dem-
onstrate that administration of aberrant transthyretin to
pregnant IL-10/ mice induces a full spectrum of
preeclampsia-like features. The relevance of using IL-10/
mice lies in the fact that IL-10 is a potent anti-inﬂammatory
and vascular cytokine.20,46,47 IL-10 is a potent inducer of
heme oxygenase-1, which has been shown to be critical for
placentation and fetal development.48,49 IL-10 and heme
oxygenase-1 exert protective effects against oxidative stress
and induce negative regulation of sFlt-1 and sEng.50e52
Thus, the absence of IL-10 may predispose to inﬂamma-
tory activities and poor vascularization at the maternal-fetal
interface. In this regard, it is tempting to speculate that
aggregated and toxic transthyretin may cause preeclampsia-
like pathological characteristics in IL-10/ mice, even at
low doses.1434The extraordinary observation of aberrant transthyretin in
preeclampsia is further supported by immunodepletion of
transthyretin from PES, which ameliorates most of the
disease features. Measurement of serum transthyretin from
normal pregnancy and preeclampsia by SELDI-TOF sug-
gested that this protein was signiﬁcantly reduced in PES
compared with NPS. On the other hand, we observed
transthyretin deposits in preeclampsia placental tissue and in
the mouse placenta from animals administered with human
transthyretin from PES. This prompted us to focus on the
aggregation properties of endogenous transthyretin, a
feature widely associated with unscheduled misfolding and
aggregation in amyloid diseases and possibly in Alzheimer
disease.24e26,44 By using several complementary approaches,
we provide evidence for aggregation of transthyretin protein
in PES and in placental tissue from preeclampsia pregnancies.
NPS and PES differed in their susceptibility to pH-dependent
aggregation that was abolished after immunodepletion of
transthyretin. Thus, we propose that preeclampsia is a disease
of protein misfolding and aggregation. A similar scenario has
been proposed for human serine protease inhibitor A1,53
although it is not yet clear how this protease inhibitor is
involved in preeclampsia. Serine protease inhibitor A1 has
been shown to undergo fragmentation, misfolding, and
aggregation in response to oxidative stress.54
Transthyretin is protective in a murine model of Alz-
heimer disease because of its ability to sequester b-amyloid
peptides in a chaperone-like manner.27,28 Our gain-of-
function studies support a similar protective role of exoge-
nous transthyretin in preeclampsia. The rescue of maternal
symptoms in mice was associated with reduction in sFlt-1
and sEng. The role of native transthyretin in inhibiting
production of anti-angiogenic factors is noteworthy because
these factors are thought to be key regulators of local and
systemic manifestations of preeclampsia.21,22 On the other
hand, immunoprecipitated transthyretin from PES induces
production of these factors in pregnant IL-10/ mice,
implying a direct role of dysregulated protein in program-
ming the events that lead to the onset of preeclampsia
pathological characteristics. We provide evidence that dys-
regulated transthyretin reaches the mouse placenta, forms
deposits, and induces placental apoptosis.
Our ﬁndings raise questions about the mechanisms and
microenvironment that lead to transthyretin misfolding and
aggregation in preeclampsia. Several factors, such as mu-
tations in transthyretin, local change in pH at membranes,
and oxidative stress, are likely to contribute to destabi-
lization of transthyretin, causing tetramer dissociation, a
rate-limiting step in transthyretin amyloidogenesis.25,42
However, both natural transthyretin and mutant variants
form aggregates and amyloid ﬁbrils.24,25,45 How may this
happen at the maternal-fetal interface during pregnancy,
even without mutations? Hypoxia is thought to be associ-
ated with the induction of endoplasmic reticulum (ER) stress
and, possibly, preeclampsia pathological characteristics.55,56
The ER is a hub for proper folding and export of peptides,ajp.amjpathol.org - The American Journal of Pathology
TTR and Pathogenesis of Preeclampsiaguided by ER-speciﬁc chaperones. ER stress can dysregu-
late the function of chaperones, resulting in export of mis-
folded proteins into circulation.56 Such a scenario is
manifest in the placenta of IUGR.57 These conditions can
also overlap in preeclampsia, leading to poor placentation.
In this context, our published studies have shown that
maternal hypoxia causes preeclampsia-like features in
pregnant mice.14 Interestingly, hypoxia has been shown to
control TTR expression and uptake.58 Thus, it is plausible
that chronic hypoxia and ER stress destabilize transthyretin
into a misfolded conformation and aggregation. More im-
portant, failure to adapt to a challenging intrauterine milieu
may trigger conformational changes in proteins, causing
aggregation and loss of function that lead to development of
preeclampsia.
Our SELDI-TOF analysis and Far Western data on
protein-protein interactions reveal novel transthyretin
binding partners, including sEng (Supplemental Figure S4
and Supplemental Table S3). Because normal transthyretin
binds to sEng, we propose that aggregated transthyretin fails
to trap factors, such as sEng, which allows such proteins to
contribute to the pathogenesis of this syndrome. Autophagy
is known to dispose unwanted proteins and maintain
homeostasis,59 but it has been shown to be impaired in
preeclampsia.60 Its impairment is caused by endoglin.60
Interestingly, dysregulated transthyretin present in PES
induces production of sFlt-1 and sEng. It is, thus, possible
that free soluble endoglin inhibits autophagy, and this effect
could be imparted by aggregated transthyretin. When
homotetrameric transthyretin transforms into misfolded
and self-aggregated structures, the binding and scavenging
potential of this protein is lost while acquiring the potential to
induce production of sFlt-1, sEng, and other unknown factors
(Figure 7B). Thus, preeclampsia pathological characteristice
associated aggregation of transthyretin is most likely an
upstream event of production of anti-angiogenic factors.
Overall, our studies provide compelling evidence for the
concept that preeclampsia is, in part, a syndrome of protein
misfolding and aggregation. These observations offer a new
framework for understanding the complex nature of
preeclampsia pathogenesis. Intriguingly, exogenous trans-
thyretin can reverse the features of the syndrome in
a humanized mouse model of preeclampsia. These studies
reveal innovative frontiers for identifying potential trans-
lational targets for therapy.Acknowledgments
We thank the members of the Sharma laboratory for critical
discussion, Phil Gruppuso for insightful comments, Sheryl-
Vi Rico for transthyretin measurement by ELISA, Paula
Weston for histological data, Christian Melle and Nico
Escher for their support in SELDI-TOF analyses, and Jus-
tine S. Fitzgerald and Andreas Brückmann for providing
patient serum samples for supplemental experiments.The American Journal of Pathology - ajp.amjpathol.orgSupplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.07.022.References
1. Roberts JM, Hubel CA: Is oxidative stress the link in the two-stage
model of pre-eclampsia? Lancet 1999, 354:788e789
2. Redman CW, Sargent IL: Latest advances in understanding
preeclampsia. Science 2005, 308:1592e1594
3. Dekker G, Sibai B: Primary, secondary and tertiary prevention of pre-
eclampsia. Lancet 2001, 357:209e215
4. Steegers EA, Dadelszen P, Duvekot JJ, Pijnenborg R: Pre-eclampsia.
Lancet 2010, 376:631e644
5. Parikh SM, Karumanchi SA: Putting pressure on pre-eclampsia. Nat
Med 2008, 14:810e812
6. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van
Asshe A: A study of placental bed spiral arteries and trophoblast
invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet
Gynaecol 1994, 101:669e674
7. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP,
Sibai BM, Epstein FH, Romero R, Thadani R, Karumanchi SA; CPEP
Study Group: Soluble endoglin and other circulating antiangiogenic
factors in preeclampsia. N Engl J Med 2006, 355:992e1005
8. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ,
Ramin SM, Kellems RE, Xia Y: Angiotensin receptor agonistic
autoantibodies induce pre-eclampsia in pregnant mice. Nat Med
2008, 14:855e862
9. Redman CW, Sargent IL: Circulating microparticles in normal
pregnancy and pre-eclampsia. Placenta 2008, 29:S73eS77
10. Zhou Y, Damsky CH, Fisher SJ: Preeclampsia is associated with
failure of human cytotrophoblasts to mimic a vascular adhesion
phenotype: one cause of defective endovascular invasion in this
syndrome? J Clin Invest 1997, 99:2152e2164
11. Hupperts B: Placental origins of preeclampsia: challenging the
current hypothesis. Hypertension 2008, 5:970e975
12. Hung TH, Skepper JN, Charnock-Jones DS, Burton GJ: Hypoxia-
reoxygenation: a potent inducer of apoptotic changes in the human
placenta and possible etiological factor in preeclampsia. Circ Res
2002, 90:1274e1281
13. Sharma S, Norris WE, Kalkunte S: Beyond the threshold: an etio-
logical bridge between hypoxia and immunity in preeclampsia. J
Reprod Immunol 2010, 85:112e116
14. Lai Z, Kalkunte S, Sharma S: A critical role of interleukin-10 in
modulating hypoxia-induced preeclampsia-like disease in mice.
Hypertension 2011, 57:505e514
15. Lim HJ, Wang H: Uterine disorders and pregnancy complications:
insights from mouse models. J Clin Invest 2010, 120:1004e1015
16. Johnson L: Cancer: clinical trials unite mice and humans. Nature
2012, 483:546e548
17. Gitler AD, Lehmann R: Modeling human diseases. Science 2012,
337:269
18. Kalkunte S, Boij SR, Norris W, Friedman J, Lai Z, Kurtis J, Lim KH,
Padbury JF, Matthiesen L, Sharma S: Sera from preeclampsia patients
elicit symptoms of human disease in mice and provide a basis for an
in vitro predictive assay. Am J Pathol 2010, 177:2387e2398
19. Hennessy A, Pilmore HL, Simmons LA, Painter DM: A deﬁciency of
placental IL-10 in preeclampsia. J Immunol 1999, 163:3491e3495
20. Kalkunte S, Nevers T, Norris WE, Sharma S: Vascular IL-10:
a protective role in preeclampsia. J Reprod Immunol 2011, 88:65e69
21. Venkatesha S, Toporsian M, Lam C, Hanai J, Yamamoto T,
Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE,
Roberts D, D’Amore PA, Epstein FH, Sellke FW, Romero R,
Sukhatme VP, Latarte M, Karumanchi SA: Soluble endoglin1435
Kalkunte et alcontributes to the pathogenesis of preeclampsia. Nat Med 2006, 12:
642e649
22. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S,
Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH,
Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like
tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction,
hypertension, and proteinuria in preeclampsia. J Clin Invest 2003,
111:649e658
23. Raz A, Goodman DS: The interaction of thyroxine with human
plasma prealbumin and with the prealbumin-retinol-binding protein
complex. J Biol Chem 1969, 244:3230e3237
24. Dobson CM: Protein folding and misfolding. Nature 2003, 426:
884e890
25. Hammarström P, Wiseman RL, Powers ET, Kelly JW: Prevention of
transthyretin amyloid disease by changing protein misfolding ener-
getics. Science 2003, 299:713e716
26. Goldsteins G, Persson H, Anderson K, Olofsson A, Dacklin I,
Edvinsson A, Saraiva MJ, Lundgren E: Exposure of cryptic epitopes
on transthyretin only in amyloid and in amyloidogenic mutants. Proc
Natl Acad Sci U S A 1999, 96:3108e3113
27. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T,
Masliah E, Roberts AR, Bartfai T: Transthyretin protects Alzheimer’s
mice from the behavioral and biochemical effects of Abeta toxicity.
Proc Natl Acad Sci U S A 2008, 105:2681e2686
28. Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA:
Neutralization of transthyretin reverses the neuroprotective effects of
secreted amyloid precursor protein (APP) in APPSW mice resulting
in tau phosphorylation and loss of hippocampal neurons: support for
the amyloid hypothesis. J Neurosci 2004, 24:7707e7717
29. Altland K, Winter P, Saraiva MJ, Suhr O: Sulﬁte and base for the
treatment of familial amyloidotic polyneuropathy: two additive
approaches to stabilize the conformation of human amyloidogenic
transthyretin. Neurogenetics 2004, 5:61e67
30. Henze A, Rohn S, Gericke B, Raila J, Schweigert FJ: Structural
modiﬁcations of serum transthyretin in rats during protein-energy
malnutrition. Rapid Commun Mass Spectrom 2008, 22:3270e3274
31. Schweigert FJ, Gericke B, Wolfram W, Kaisers U, Dudenhausen JW:
Peptide and protein proﬁles in serum and follicular ﬂuid of women
undergoing IVF. Hum Reprod 2006, 21:2960e2968
32. Gericke B, Raila J, Deja M, Rohn S, Donaubauer B, Nagl B,
Haebel S, Schweigert FJ, Kaisers U: Alteration of transthyretin
microheterogeneity in serum of multiple trauma patients. Biomark
Insights 2007, 2:299e306
33. Burnum KE, Tranguch S, Mi D, Daikoku T, Dey SK, Caprioli RM:
Imaging mass spectrometry reveals unique protein proﬁles during
embryo implantation. Endocrinology 2008, 149:3274e3278
34. McKinnon B, Li H, Richard K, Mortimer R: Synthesis of thyroid
hormone binding proteins transthyretin and albumin by human
trophoblast. J Clin Endocrinol Metab 2005, 90:6714e6720
35. Graham CH, Connelly I, MacDougall JR, Kerbel RS, Stetler-
Stevenson WG, Lala PK: Establishment and characterization of ﬁrst
trimester human trophoblast cells with extended lifespan. Exp Cell
Res 1993, 206:204e211
36. Kalkunte S, Lai Z, Tewari N, Chichester C, Romero R, Padbury J,
Sharma S: In vitro and in vivo evidence for lack of endovascular
remodeling by third trimester trophoblasts. Placenta 2008, 29:871e878
37. Reixach N, Foss TR, Santelli E, Pascual J, Kelly JW, Buxbaum JN:
Human-murine transthyretin heterotetramers are kinetically stable and
non-amyloidogenic: a lesson in the generation of transgenic models
of diseases involving oligomeric proteins. J Biol Chem 2008, 283:
2098e2107
38. Wu Y, Li Q, Chen XZ: Detecting protein-protein interactions by Far
western blotting. Nat Protoc 2007, 2:3278e3284
39. Guntern R, Bouras C, Hof PR, Vallet PG: An improved thioﬂavine S
method for staining neuroﬁbrillary tangles and senile plaques in
Alzheimer’s disease. Experientia 1992, 48:8e10143640. Schweigert FJ, Wirth K, Raila J: Characterization of the micro-
heterogeneity of transthyretin in plasma and urine using SELDI-TOF-
MS immunoassay. Proteome Sci 2004, 2:5
41. Vorderwülbecke S, Cleverley S, Weinberger SR, Wiesner A: Protein
quantiﬁcation by the SELDI-TOF-MSebased ProteinChip System.
Nat Methods 2005, 2:393e395
42. Kelly JW: The alternative conformations of amyloidogenic proteins
and their multi-step assembly pathways. Curr Opin Struct Biol 1998,
8:101e106
43. Lai Z, Colón W, Kelly JW: The acid-mediated denaturation pathway
of transthyretin yields a conformational intermediate that can self-
assemble into amyloid. Biochemistry 1996, 35:6470e6482
44. Koo EH, Lansbury PT Jr., Kelly JW: Amyloid diseases: abnormal
protein aggregation in neurodegeneration. Proc Natl Acad Sci U S A
1999, 96:9989e9990
45. Karlsson A, Olofsson A, Eneqvist T, Sauer-Eriksson AE: Cys114-
linked dimers of transthyretin are compatible with amyloid forma-
tion. Biochemistry 2005, 44:13063e13070
46. Thaxton JE, Sharma S: Interleukin-10: a multifaceted agent of
pregnancy. Am J Reprod Immunol 2010, 63:482e491
47. Didion SP, Kinzenbaw DA, Schrader LI, Chu Y, Faraci FM:
Endogenous IL-10 inhibits angiotensin II-induced vascular dysfunc-
tion. Hypertension 2009, 54:619e624
48. Lee TS, Chau LY: Heme oxygenase-1 mediates anti-inﬂammatory
effect of interleukin-10 in mice. Nat Med 2002, 8:240e246
49. Zenclussen AC, Lim E, Knoeller S, Knackstedt M, Hertwig K,
Hagen E, Klapp BF, Arck PC: Heme oxygenases in pregnancy II:
HO-2 is downregulated in human pathologic pregnancies. Am J
Reprod Immunol 2003, 50:66e76
50. HuetO, LaemmelE, FuY,DupicL,ApricoA,AndrewsKL,Moore SL,
Harrois A, Meikle PL, Vicaut E, Chin-Dusting JP, Duranteau J: Inter-
leukin 10 antioxidant effect decreases leukocytes/endothelial interac-
tion induced by tumor necrosis factor a. Shock 2013, 39:83e88
51. Soares MP, Bach FH: Heme oxygenase 1: from biology to therapeutic
potential. Trends Immunol 2009, 15:50e58
52. Cudmore M, Ahmed S, Al-Ani B, Fujisawa T, Coxall H,
Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW,
Ahmed A: Negative regulation of soluble Flt-1 and soluble endoglin
release by heme oxygenase-1. Circulation 2007, 115:1789e1797
53. Buhimschi IA, Zhao Z, Funai EF, Harris N, Bernstein IM, Saade GR,
Buhimschi CS: Proteomic proﬁling of urine identiﬁes speciﬁc frag-
ments of SERPINA1 and albumin as biomarkers of preeclampsia. Am
J Obstet Gynecol 2008, 199:551.e1e551.e16
54. Matheson NR, Wong PS, Travis J: Enzymatic inactivation of human
alpha-1-proteinase inhibitor by neutrophil myeloperoxidase. Biochem
Biophys Res Commun 1979, 88:402e409
55. Feldman DE, Chauhan V, Koong AC: The unfolded protein response:
a novel component of the hypoxic stress response in tumors. Mol
Cancer Res 2005, 3:597e605
56. Redman CW: The endoplasmic reticulum stress of placental impov-
erishment. Am J Pathol 2008, 173:311e314
57. Yung HW, Calabrese S, Hynx D, Hemmings BA, Cetin I, Charnock-
Jones DS, Burton GJ: Evidence of placental translation, inhibition
and endoplasmic reticulum stress in the etiology of human intra-
uterine growth restriction. Am J Pathol 2008, 173:451e462
58. Patel J, Landers K, Li H, Mortimer RH, Richard K: Oxygen
concentration regulates expression and uptake of transthyretin,
a thyroxine binding protein, in JEG-3 choriocarcinoma cells. Placenta
2011, 32:128e133
59. Klionsky DJ: Good riddance to bad rubbish. Nature 2006, 441:
819e820
60. Nakashima A, Yamanaka-Tatemastu M, Fujita N, Koizumi K,
Shima T, Yoshida T, Nikaido T, Okamoto A, Yoshimori T, Siato S:
Impaired autophagy by soluble endoglin, under physiological
hypoxia in early pregnant period, is involved in poor placentation and
preeclampsia. Autophagy 2013, 9:1e14ajp.amjpathol.org - The American Journal of Pathology
